Science and Technology Part 4: Genome India, Biotech Startups and the Bio-E3 Push, Exam-Ready Notes

Category: Civil Exams · Series: Science and Technology (GS Paper 3) · Read time: ~9 minutes

The bioeconomy file covers the Genome India Project, the Covid-vaccine record, the CAR-T breakthrough, and the policy stack (BIRAC, Bio-E3 2024). This note assembles the cluster in exam-ready form.

Table of Contents

1. The Genome India Project
2. The Vaccine Record and Bio-Manufacturing
3. The Frontier: CAR-T, CRISPR Therapies
4. The Policy Stack: BIRAC and Bio-E3
5. The Regulation and Ethics Layer
6. How Exams Probe This Topic
7. Quick Revision: One-Glance Facts

1. The Genome India Project

• The card. Genome India Project (GIP) — launched 2020 by the Department of Biotechnology, a consortium of 20 institutions (IISc Bengaluru coordinating); goal: whole-genome sequencing of 10,000 Indians — the target was completed in early 2025, with the dataset released to researchers through controlled access — the current milestone to cite.
• Why India-specific. India’s population holds ~4,600 distinct groups with heavy endogamy — founder effects enrich disease-specific variants that global reference genomes miss; Indian data improves variant interpretation, disease-risk prediction and pharmacogenomics (drug response) for Indians.
• The global context. Human Genome Project (1990-2003, first draft); the complete T2T genome (2022); the UK’s 100,000 Genomes Project — India’s dataset is the largest single-country effort focused on such genetic diversity.
• Applications. Precision medicine (targeted cancer therapy, drug dosing), rare-disease diagnosis (India’s ~7 crore rare-disease patients), population-health and ancestry studies, forensics.

2. The Vaccine Record and Bio-Manufacturing

• The platforms. Covaxin (Bharat Biotech’s inactivated-virus vaccine, co-developed with ICMR); Covishield (Serum Institute’s licensed AZ vaccine — SII is the world’s largest vaccine maker, supplying ~60% of global children’s vaccines); ZyCoV-D (Zydus’s DNA vaccine — the world’s first DNA vaccine authorised for Covid, needle-free delivery); CORBEVAX (protein-subunit). India delivered 2+ billion doses through CoWIN — the world’s largest vaccination drive, with Vaccine Maitri exporting ~10 crore doses (see the IR series, Part 8).
• The new platforms. Gennova’s indigenous mRNA vaccine (thermo-stable design); the pneumococcal and cervical-vaccine pipeline; WHO prequalification of a widening Indian portfolio — the “pharmacy of the world” position.
• The biosimilar era. The 2024-25 semaglutide patent expiries opened a major biosimilar opportunity for Indian firms — the current commercial story.

3. The Frontier: CAR-T, CRISPR Therapies

• NexCAR19 (2024). India’s first indigenous CAR-T cell therapy (IIT Bombay–Tata Memorial collaboration), approved 2024 for certain blood cancers — priced around ₹30-40 lakh against the ₹3-4 crore imported equivalents — the “cell therapy at a tenth of the cost” milestone and a guaranteed current-affairs item.
• Casgevy (2023-24). The world’s first approved CRISPR-based medicine (sickle-cell disease and beta-thalassemia) — the gene-editing therapeutic milestone; cost (~₹2-3 crore) keeps accessibility the Indian question.
• The National Sickle Cell Anaemia Elimination Mission (2023) — screening ~7 crore people in the tribal belt by 2047 — the programme that pairs with the therapy frontier.
• Stem cells and synthetic biology. iPSC (Yamanaka) reprogramming for regenerative medicine; Bio-E3’s biofoundries (design-build-test-learn infrastructure for engineered biology — biofuels, enzymes, bioplastics); the dual-use biosecurity debate under the BTWC.

4. The Policy Stack: BIRAC and Bio-E3

• BIRAC. Biotechnology Industry Research Assistance Council (2012, DBT’s PSU) — the startup facilitator; the BIG (Biotechnology Ignition Grant) for idea-stage proof-of-concept; biotech startups grew from ~50 (2012) to ~9,000+ (2025) — the 20x-in-a-decade claim.
• Bio-E3 (2024). The “Biotechnology for Economy, Environment and Employment” policy (Cabinet-approved September 2024) — biomanufacturing and biofoundries as the “IT-moment for BT”; targets the bioeconomy growing from ~$130-150 billion (2024) to $300 billion by 2030.
• The funding layer. The National Biopharma Mission (2017-24); the 2024 Budget’s ₹1 lakh crore 50-year R&D corpus (Part 6’s detail) partially steers to deep-tech bio.

5. The Regulation and Ethics Layer

• The stack. The 1989 rDNA Rules (the GEAC family — see Part 3), the New Drugs and Clinical Trials Rules 2019 (ethics, compensation), the SDN gene-editing exemption discussions; the DPDP Act 2023’s treatment of health/genetic data — the genetic-privacy debate around GIP’s controlled-access model.
• The ethics line. Somatic editing is permitted; germline editing is globally prohibited (the He Jiankui 2018 case) — India aligns with the WHO’s 2021 governance framework.

6. How Exams Probe This Topic

• Prelims: GIP (2020; 10,000 genomes; 2025 completion); ZyCoV-D’s first-DNA-vaccine status; NexCAR19 (2024); Casgevy; BIRAC (2012) and the startup count; Bio-E3 (2024); the bioeconomy’s $ figure; the sickle-cell mission; NDCT 2019.
• Mains: “Genome India builds the precision-medicine foundation — examine the science and the governance needs”; “From Covaxin to NexCAR19, Indian biotech has climbed the value chain — evaluate with the Bio-E3 strategy”; “The bioeconomy’s IT-moment requires talent and capital — discuss the ecosystem gaps.”
• Cross-links. GM regulation (Part 3), R&D funding (Part 6), DPDP (the site’s DPDP notes).

7. Quick Revision: One-Glance Facts

• GIP. 2020 launch; 10,000 genomes (2025); 4,600 population groups; precision-medicine base.
• Vaccines. Covaxin-Covishield-ZyCoV-D-CORBEVAX; 2+ bn doses; SII ~60% of global children’s vaccines.
• Therapy. NexCAR19 (2024, ~₹30-40 lakh); Casgevy (first CRISPR medicine); sickle-cell mission (2023/2047).
• Policy. BIRAC 2012 (~9,000 startups); Bio-E3 2024; bioeconomy ~$150 bn → $300 bn by 2030.
• Regulation. NDCT 2019; germline ban; DPDP-health-data interface.

Conclusion. The biotech file is a record (the vaccine era), a project (GIP’s completion), a milestone (NexCAR19), and a policy (Bio-E3) — held together by the “IT-to-BT” narrative. Hold the numbers (10,000 genomes; 9,000 startups; ~$150 bn) and the two frontier cases, and both prelims facts and the mains ecosystem argument are covered.